A.D. Chetiyawardana

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life

M.H. Cullen, Lucinda Billingham, C.M. Woodroffe et al. · Journal of Clinical Oncology · 1999 · 449 citations

Medicine, Oncology, Pharmacology +12

Optimal Planning Target Volume for Stage I Testicular Seminoma: A Medical Research Council Randomized Trial

Sophie D. Fosså, A. Horwich, JM Russell et al. · Journal of Clinical Oncology · 1999 · 385 citations

Medicine, Oncology, Radiation Oncology +17

Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare

M.H. Cullen, RameshC. Joshi, A.D. Chetiyawardana et al. · British Journal of Cancer · 1988 · 124 citations · Full text

Medicine, Oncology, Pharmacology +9

Combination Bleomycin, Ifosfamide, and Cisplatin Chemotherapy in Cervical Cancer

E. J. Buxton, C. A. Meanwell, C. Hilton et al. · JNCI Journal of the National Cancer Institute · 1989 · 87 citations

Medicine, Oncology, Pharmacology +15